These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 25810245)

  • 1. Influence of CYP2C19 loss-of-function variants on the metabolism of clopidogrel in patients from north-western China.
    Lin R; Zhang L; Zhang P; Zhou L; Liu T; Li Y; Zhang W; Wang W; Zhang J
    J Clin Pharm Ther; 2015 Jun; 40(3):308-14. PubMed ID: 25810245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of cytochrome P450 2C19 polymorphism on adverse cardiovascular events after drug-eluting stent implantation in a large Hakka population with acute coronary syndrome receiving clopidogrel in southern China.
    Zhong Z; Hou J; Zhang Q; Li B; Li C; Liu Z; Yang M; Zhong W; He X; Wu H; Zhong M; Zhao P
    Eur J Clin Pharmacol; 2018 Apr; 74(4):423-431. PubMed ID: 29243114
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of CYP3A5 polymorphism on platelet reactivity at percutaneous coronary intervention and after 9 months of aspirin and clopidogrel therapy in Japanese patients with coronary artery disease.
    Hokimoto S; Chitose T; Mizobe M; Akasaka T; Arima Y; Kaikita K; Iwashita S; Morita K; Miyazaki H; Oniki K; Matsui K; Nakagawa K; Ogawa H
    Eur J Clin Pharmacol; 2014 Jun; 70(6):667-73. PubMed ID: 24763934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of genetic and non-genetic factors on the plasma concentrations of the clopidogrel metabolite (SR26334) among Chinese patients.
    Zhou H; Meng S; Zhao J; Dong J; Xu A; Wang F; Guzalnur T; Xin J; Zhang J; Wang J; Cai W
    Clin Chim Acta; 2013 Feb; 416():50-3. PubMed ID: 23201489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic polymorphisms of CYP2C19 influences the response to clopidogrel in ischemic heart disease patients in the South Indian Tamilian population.
    Subraja K; Dkhar SA; Priyadharsini R; Ravindra BK; Shewade DG; Satheesh S; Sridhar MG; Narayan SK; Adithan C
    Eur J Clin Pharmacol; 2013 Mar; 69(3):415-22. PubMed ID: 22955794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of CYP2C19 Genetic Polymorphisms on the Pharmacokinetic and Pharmacodynamic Properties of Clopidogrel and Its Active Metabolite in Healthy Chinese Subjects.
    Song BL; Wan M; Tang D; Sun C; Zhu YB; Linda N; Fan HW; Zou JJ
    Clin Ther; 2018 Jul; 40(7):1170-1178. PubMed ID: 30017169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of CYP2C19 genotype on the time course of platelet aggregation inhibition after clopidogrel administration.
    Kim HS; Cho DY; Park BM; Bae SK; Yoon YJ; Oh M; Ghim JL; Kim EY; Kim DH; Shin JG
    J Clin Pharmacol; 2014 Aug; 54(8):850-7. PubMed ID: 24214141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The pharmacokinetic and pharmacodynamic interaction of clopidogrel and cilostazol in relation to CYP2C19 and CYP3A5 genotypes.
    Kim HS; Lim Y; Oh M; Ghim JL; Kim EY; Kim DH; Shin JG
    Br J Clin Pharmacol; 2016 Feb; 81(2):301-12. PubMed ID: 26426352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of selected genetic factors on clopidogrel inactive metabolite level and antiplatelet response in patients after percutaneous coronary intervention.
    Adamiak-Giera U; Czerkawska A; Olędzki S; Kurzawski M; Safranow K; Jastrzębska M; Gawrońska-Szklarz B
    Pharmacol Rep; 2021 Apr; 73(2):583-593. PubMed ID: 33270185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CYP2C19 polymorphisms and coronary heart disease risk factors synergistically impact clopidogrel response variety after percutaneous coronary intervention.
    Liu T; Yin T; Li Y; Song LQ; Yu J; Si R; Zhang YM; He Y; Guo WY; Wang HC
    Coron Artery Dis; 2014 Aug; 25(5):412-20. PubMed ID: 24608794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CYP2C19 genotypes and their impact on clopidogrel responsiveness in percutaneous coronary intervention.
    Mejin M; Tiong WN; Lai LY; Tiong LL; Bujang AM; Hwang SS; Ong TK; Fong AY
    Int J Clin Pharm; 2013 Aug; 35(4):621-8. PubMed ID: 23661171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic polymorphisms of CYP2C19 2 and ABCB1 C3435T affect the pharmacokinetic and pharmacodynamic responses to clopidogrel in 401 patients with acute coronary syndrome.
    Wang XQ; Shen CL; Wang BN; Huang XH; Hu ZL; Li J
    Gene; 2015 Mar; 558(2):200-7. PubMed ID: 25542807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation between the CYP2C19 phenotype status and the results of three different platelet function tests in cardiovascular disease patients receiving antiplatelet therapy: an emphasis on newly introduced platelet function analyzer-200 P2Y test.
    Li S; Choi JL; Guo LZ; Goh RY; Kim BR; Woo KS; Kim MH; Han JY
    Ann Lab Med; 2016 Jan; 36(1):42-8. PubMed ID: 26522758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The influence of genetic polymorphism of Cyp2c19 isoenzyme on the pharmacokinetics of clopidogrel and its metabolites in patients with cardiovascular diseases.
    Karaźniewicz-Łada M; Danielak D; Rubiś B; Burchardt P; Oszkinis G; Główka F
    J Clin Pharmacol; 2014 Aug; 54(8):874-80. PubMed ID: 24782221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of the effect of CYP2C19 gene properties on the anti-platelet aggregation of clopidogrel after carotid artery stenting under network pharmacology.
    Li P; Cao M; Liu L; Chen L; Liang S; Wang Y
    BMC Pharmacol Toxicol; 2024 Jun; 25(1):34. PubMed ID: 38845014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interaction analysis between genetic polymorphisms and pharmacodynamic effect in patients treated with adjunctive cilostazol to dual antiplatelet therapy: results of the ACCEL-TRIPLE (Accelerated Platelet Inhibition by Triple Antiplatelet Therapy According to Gene Polymorphism) study.
    Kim IS; Jeong YH; Park Y; Yoon SE; Kwon TJ; Park JR; Hwang SJ; Koh EH; Kwak CH; Hwang JY; Kim S
    Br J Clin Pharmacol; 2012 Apr; 73(4):629-40. PubMed ID: 22007612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Association of CYP2C19 gene polymorphisms with long-term recurrent risk of ischemic stroke among ethnic Han Chinese from Fujian].
    Fang L; Zhao Y; Wang N; Yang Z; Huang H; Lin M
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2015 Dec; 32(6):871-6. PubMed ID: 26663068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of cytochrome P450 2C19 and paraoxonase 1 polymorphisms on antiplatelet response to clopidogrel therapy in patients with coronary artery disease.
    Tresukosol D; Suktitipat B; Hunnangkul S; Kamkaew R; Poldee S; Tassaneetrithep B; Likidlilid A
    PLoS One; 2014; 9(10):e110188. PubMed ID: 25329996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Value of CYP2C19 Genetic Testing for Guiding the Antiplatelet Therapy in a Chinese Population.
    Shen DL; Wang B; Bai J; Han Q; Liu C; Huang XH; Zhang JY
    J Cardiovasc Pharmacol; 2016 Mar; 67(3):232-6. PubMed ID: 26727381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Relationship between ATP-binding cassette subfamily B member 1 and cytochrome P450 2C19 polymorphisms and the effect of clopidogrel post percutaneous coronary intervention in patients with acute coronary syndrome].
    Zhou CF; Ren YH; Song YQ; Yi J; Han BS; Xue Q; Fu ZH; Li DY
    Zhonghua Xin Xue Guan Bing Za Zhi; 2016 Apr; 44(4):309-14. PubMed ID: 27112608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.